S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
pixel
Log in
NASDAQ:ZFGN

Zafgen Stock Forecast, Price & News

$19.61
+0.01 (+0.05 %)
(As of 01/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.56
Now: $19.61
$20.22
50-Day Range
$0.99
MA: $18.73
$25.06
52-Week Range
$0.62
Now: $19.61
$2.76
Volume34,430 shs
Average Volume360,199 shs
Market Capitalization$734.79 million
P/E RatioN/A
Dividend YieldN/A
Beta0.27
Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.
Zafgen logo

MarketRank

Overall MarketRank

0.85 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZFGN
CUSIPN/A
Phone617-622-4003
Employees38

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.35 per share

Profitability

Net Income$-45,410,000.00

Miscellaneous

Market Cap$734.79 million
Next Earnings DateN/A
OptionableOptionable
$19.61
+0.01 (+0.05 %)
(As of 01/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZFGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zafgen (NASDAQ:ZFGN) Frequently Asked Questions

How has Zafgen's stock been impacted by COVID-19?

Zafgen's stock was trading at $0.8501 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZFGN stock has increased by 2,206.8% and is now trading at $19.61.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Zafgen?

Wall Street analysts have given Zafgen a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zafgen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Zafgen's earnings last quarter?

Zafgen Inc (NASDAQ:ZFGN) issued its quarterly earnings results on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) EPS for the quarter, hitting analysts' consensus estimates of ($0.19).
View Zafgen's earnings history
.

Who are some of Zafgen's key competitors?

What other stocks do shareholders of Zafgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include SCYNEXIS (SCYX), CA (CA), Endologix (ELGX), Energy Transfer (ET), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Pfizer (PFE), Spectrum Pharmaceuticals (SPPI) and Esperion Therapeutics (ESPR).

Who are Zafgen's key executives?

Zafgen's management team includes the following people:
  • Mr. Jeffrey S. Hatfield, CEO & Director (Age 61)
  • Ms. Patricia L. Allen, Chief Financial Officer (Age 57)
  • Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 49)
  • Dr. James E. Vath, Head of Discovery & Devel. (Age 58)
  • Mr. Brian P. McVeigh, Chief Bus. Officer (Age 46)

What is Zafgen's stock symbol?

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

How do I buy shares of Zafgen?

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zafgen's stock price today?

One share of ZFGN stock can currently be purchased for approximately $19.61.

How big of a company is Zafgen?

Zafgen has a market capitalization of $734.79 million. The biopharmaceutical company earns $-45,410,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Zafgen employs 38 workers across the globe.

What is Zafgen's official website?

The official website for Zafgen is www.zafgen.com.

How can I contact Zafgen?

Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.